SarcopeniaNCT02912130
Exercise and Nutrition Interventions in Age-related Sarcopenia
A study testing Protein Supplementation, Aerobic Exercise and Resistance Exercise in people with Sarcopenia and Muscular Atrophy, run by Liverpool Hope University at 1 site in United Kingdom.
Trial summary
This project will investigate the synergistic effects of Aerobic and Resistance type Exercise, in combination with Protein Supplementation, on; Body Composition, Musculoskeletal Functioning, Nutritional Status and Quality of Life in Age-related Sarcopenia. Read more about this study
- Who is it for?
- Ages 60 to 90 yearsHealthy volunteers can take part
- Conditions the study is for
- Sarcopenia, Muscular Atrophy
- What is being tested?
- Protein Supplementation, Aerobic Exercise and Resistance Exercise
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 110 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Sep 2016to Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 to 90 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Male and Female participants
- 60 - 90 years of age
- Resident in North West, England, UK
- BMI 18.5-30 kg/m
- Can speak and understand English
- Willing to consent and follow the study procedures
Who cannot join
- Recent (i.e. past 3 months) or concurrent participation in any clinical trial or dietary and/or exercise intervention program
- Self-reported lactose intolerance
- Uncontrolled diabetes (HbA1C >10)
- Uncontrolled Hypertension (160/100) and uncontrolled hypotension (<100 systolic)
- Treatment with Beta Blockers, Calcium Channel Blockers, Digitalis, Bronchodilator,
- Diuretics, Vasodilators
Show all 11Show fewer
- Current hormone therapy such as insulin, testosterone or hormone replacement therapy
- History of falls/osteoporosis
- Major psychological/mental illness
- Medical conditions that precluded safe participation in an exercise program
- Other major systemic diseases: Liver and kidney diseases, Advanced gastrointestinal disorders, Cardiovascular Diseases, Advanced chronic obstructive pulmonary disease, Advanced Rheumatoid Arthritis, Cancer
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Liverpool Hope University
Liverpool, Merseyside, L16 9JD
About this study
Official title: The Multidimensional Effects of Exercise and Nutritional Interventions on Musculoskeletal Functioning, Nutritional Status and Quality of Life in Age-related Sarcopenia
This project will investigate the synergistic effects of Aerobic and Resistance type Exercise, in combination with Protein Supplementation, on; Body Composition, Musculoskeletal Functioning, Nutritional Status and Quality of Life in Age-related Sarcopenia.
Read the detailed description
Musculoskeletal ageing is an inevitable process associated with profound morphological and functional changes that will ultimately transition an individual from independent, to dependable living, relying heavily on personal health care for survival. The United Kingdom (UK) population aged over 65 years is expected to rise from 8.8 to 11.3 million by 2025. As life expectancy increases due to advances in medical treatment, an age-related disease termed sarcopenia, has become more prevalent in the elderly. Sarcopenia, described as the loss of musculoskeletal mass, strength and/or physical functioning with age, manifests after the 6th decade and rapidly increases after the 8th decade, resulting in a deterioration of health status and quality of life. To manage the looming health and economic consequences of sarcopenia, suitable therapeutic strategies to manage the condition are warranted. Therefore, this randomised control trial (RCT) will investigate the effects of 16-weeks of exercise and nutritional interventions in inactive senior citizens (60 - 90 years old).
- Conditions
- Sarcopenia, Muscular Atrophy
- Being tested
- Protein Supplementation, Aerobic Exercise, Resistance Exercise
- Keywords
- Exercise, Nutrition, Sarcopenia, Healthy Ageing, Elderly, Muscular Hypertrophy
- Medical subject headings
- Sarcopenia, Muscular Atrophy, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Protein SupplementationDietary supplement
1.2-1.5g/kg/body weight per day
Aerobic ExerciseOther
30-60 minutes per week of moderate intensity exercise
Resistance ExerciseOther
60 minutes per week of progressive resistance training
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | No Intervention |
| Exercise | Experimental | 1. Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise
2. Resistance Exercise i.e. 60 minutes per week of progressive resistance training Receives: Other: Aerobic Exercise; Other: Resistance Exercise |
| Exercise+Nutrition | Experimental | 1. Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise
2. Dietary Supplement i.e. Protein Supplementation 1.2-1.5g/kg/body weight per day Receives: Dietary Supplement: Protein Supplementation; Other: Aerobic Exercise; Other: Resistance Exercise |
| Nutrition | Experimental | Dietary Supplement: Protein Supplementation i.e. 1.2-1.5g/kg/body weight per day Receives: Dietary Supplement: Protein Supplementation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Body Composition: Lean Muscle/Fat Tissue 1) appendicular lean mass (kg) divided by height (meters-squared) and 2) appendicular lean mass divided by body mass index
Measured: 16 weeks
Secondary outcomes (19)
Grip Strength: Hand Grip Dynanometer (kg)
Measured: 16 weeks
Gait speed during timed 4-meter walk (m/s)
Measured: 16 Weeks
Time to complete five chair rises (m/s)
Measured: 16 Weeks
Balance assessment: 1) feet side to side, 2) semi-tandem, 3) full tandem, and 4) single leg. Scored as Yes or No.
Measured: 16 Weeks
Isometric Strength - Knee Flexion/Extension: Dynanometer (Nm/Kg)
Measured: 16 Weeks
Muscle Fatigue: Upper & Lower limb: 25% of MVC during 60 seconds using Electromyography (EMG), measured in millivolts (mV)
Measured: 16 Weeks
Exercise Tolerance: Six Minute Walk Test (metres)
Measured: 16 Weeks
10-metre Gait analysis during habitual walking speed using Electromyography (EMG)
Measured: 16 Weeks
10-metre Gait analysis during habitual walking speed using Three-Dimensional Motion Capture - 1) Spatiotemporal, 2) Kinematics
Measured: 16 Weeks
Biochemical: Glycated Haemoglobin (HBA1c) (%)
Measured: 16 Weeks
Biochemical: C-Reactive Protein (CRP) (mg/L)
Measured: 16 Weeks
Biochemical: Insulin-Like Growth Factor 1 (IGF-1) (ng/ml)
Measured: 16 Weeks
Arterial Pressure: Pulse Wave Velocity (m/s)
Measured: 16 Weeks
Energy Balance: Periodic Food Diary (Kcal)
Measured: 16 Weeks
World Health Organization Quality Of Life Assessment (WHOQOL): Each question is scored from 1-5 on a response scale
Measured: 16 Weeks
Short-Form Health Survey (SF-12): Each question is scored between 1-6 on a response scale
Measured: 16 Weeks
Activities of Daily Living (ADL): Each response is scored as either: 0 or 1
Measured: 16 Weeks
Mini-Mental State Examination (MMSE): Each correct response is scored as 1 point
Measured: 16 Weeks
Nutritional Status: Mini-Nutritional Assessment (MNA) - Classified as (Low, Moderate, High risk)
Measured: 16 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Sep 2016 (estimated)
- Study startSep 2016
- Primary completionDec 2023
- Study completionDec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (14)Papers the sponsor has linked to this study.
- Other trials for SarcopeniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Enrolment
- 110 participants (actual)
Sponsor and investigators
- Lead sponsor
- Liverpool Hope University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Omid Khaiyat, MD, PhD, Liverpool Hope University
- Investigators
- Dr Omid Alizadehkhaiyat, MD, PhD, Principal investigator, Liverpool Hope University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02912130
- Sponsor's protocol ID
- LiverpoolHU
- Status last verified
- Apr 2022
- First submitted
- 12 Sep 2016
- Last updated
- 11 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Undecided
Publications
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13.
PubMed 20392703Witard OC, Wardle SL, Macnaughton LS, Hodgson AB, Tipton KD. Protein Considerations for Optimising Skeletal Muscle Mass in Healthy Young and Older Adults. Nutrients. 2016 Mar 23;8(4):181. doi: 10.3390/nu8040181.
PubMed 27023595Lourenco RA, Perez-Zepeda M, Gutierrez-Robledo L, Garcia-Garcia FJ, Rodriguez Manas L. Performance of the European Working Group on Sarcopenia in Older People algorithm in screening older adults for muscle mass assessment. Age Ageing. 2015 Mar;44(2):334-8. doi: 10.1093/ageing/afu192. Epub 2014 Dec 23.
PubMed 25539836Yu SC, Khow KS, Jadczak AD, Visvanathan R. Clinical Screening Tools for Sarcopenia and Its Management. Curr Gerontol Geriatr Res. 2016;2016:5978523. doi: 10.1155/2016/5978523. Epub 2016 Feb 4.
PubMed 26966433Churchward-Venne TA, Holwerda AM, Phillips SM, van Loon LJ. What is the Optimal Amount of Protein to Support Post-Exercise Skeletal Muscle Reconditioning in the Older Adult? Sports Med. 2016 Sep;46(9):1205-12. doi: 10.1007/s40279-016-0504-2.
PubMed 26894275Kraschnewski JL, Sciamanna CN, Poger JM, Rovniak LS, Lehman EB, Cooper AB, Ballentine NH, Ciccolo JT. Is strength training associated with mortality benefits? A 15year cohort study of US older adults. Prev Med. 2016 Jun;87:121-127. doi: 10.1016/j.ypmed.2016.02.038. Epub 2016 Feb 24.
PubMed 26921660Witard OC, McGlory C, Hamilton DL, Phillips SM. Growing older with health and vitality: a nexus of physical activity, exercise and nutrition. Biogerontology. 2016 Jun;17(3):529-46. doi: 10.1007/s10522-016-9637-9. Epub 2016 Feb 15.
PubMed 26878863Chang SF, Lin PL. Systematic Literature Review and Meta-Analysis of the Association of Sarcopenia With Mortality. Worldviews Evid Based Nurs. 2016 Apr;13(2):153-62. doi: 10.1111/wvn.12147. Epub 2016 Feb 4.
PubMed 26844538Csapo R, Alegre LM. Effects of resistance training with moderate vs heavy loads on muscle mass and strength in the elderly: A meta-analysis. Scand J Med Sci Sports. 2016 Sep;26(9):995-1006. doi: 10.1111/sms.12536. Epub 2015 Aug 24.
PubMed 26302881Xu ZR, Tan ZJ, Zhang Q, Gui QF, Yang YM. Clinical effectiveness of protein and amino acid supplementation on building muscle mass in elderly people: a meta-analysis. PLoS One. 2014 Sep 30;9(9):e109141. doi: 10.1371/journal.pone.0109141. eCollection 2014.
PubMed 25268791Komar B, Schwingshackl L, Hoffmann G. Effects of leucine-rich protein supplements on anthropometric parameter and muscle strength in the elderly: a systematic review and meta-analysis. J Nutr Health Aging. 2015 Apr;19(4):437-46. doi: 10.1007/s12603-014-0559-4.
PubMed 25809808Ko SU, Hausdorff JM, Ferrucci L. Age-associated differences in the gait pattern changes of older adults during fast-speed and fatigue conditions: results from the Baltimore longitudinal study of ageing. Age Ageing. 2010 Nov;39(6):688-94. doi: 10.1093/ageing/afq113. Epub 2010 Sep 10.
PubMed 20833863Kirk B, Mooney K, Vogrin S, Jackson M, Duque G, Khaiyat O, Amirabdollahian F. Leucine-enriched whey protein supplementation, resistance-based exercise, and cardiometabolic health in older adults: a randomized controlled trial. J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):2022-2033. doi: 10.1002/jcsm.12805. Epub 2021 Sep 14.
PubMed 34520104Kirk B, Mooney K, Amirabdollahian F, Khaiyat O. Exercise and Dietary-Protein as a Countermeasure to Skeletal Muscle Weakness: Liverpool Hope University - Sarcopenia Aging Trial (LHU-SAT). Front Physiol. 2019 Apr 25;10:445. doi: 10.3389/fphys.2019.00445. eCollection 2019.
PubMed 31133863
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Multidimensional Effects of Exercise and Nutritional Interventions on Musculoskeletal Functioning, Nutritional Status and Quality of Life in Age-related Sarcopenia
- ClinicalTrials.gov ID
- NCT02912130
- Acronym / sponsor ID
- LiverpoolHU
- Conditions
- Sarcopenia, Muscular Atrophy
- Keywords
- Exercise, Nutrition, Sarcopenia, Healthy Ageing, Elderly, Muscular Hypertrophy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 110 participants (actual)
- Lead sponsor
- Liverpool Hope UniversityUniversity, hospital or other
- Study start
- Sep 2016 (actual)
- Primary completion
- Dec 2023 (actual)
- Study completion
- Dec 2023 (actual)
- First posted
- 23 Sep 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This project will investigate the synergistic effects of Aerobic and Resistance type Exercise, in combination with Protein Supplementation, on; Body Composition, Musculoskeletal Functioning, Nutritional Status and Quality of Life in Age-related Sarcopenia.
Detailed description
Musculoskeletal ageing is an inevitable process associated with profound morphological and functional changes that will ultimately transition an individual from independent, to dependable living, relying heavily on personal health care for survival. The United Kingdom (UK) population aged over 65 years is expected to rise from 8.8 to 11.3 million by 2025. As life expectancy increases due to advances in medical treatment, an age-related disease termed sarcopenia, has become more prevalent in the elderly. Sarcopenia, described as the loss of musculoskeletal mass, strength and/or physical functioning with age, manifests after the 6th decade and rapidly increases after the 8th decade, resulting in a deterioration of health status and quality of life. To manage the looming health and economic consequences of sarcopenia, suitable therapeutic strategies to manage the condition are warranted. Therefore, this randomised control trial (RCT) will investigate the effects of 16-weeks of exercise and nutritional interventions in inactive senior citizens (60 - 90 years old).
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Control | No intervention | –No Intervention |
| Exercise | Experimental | Other: Aerobic Exercise, Other: Resistance Exercise1. Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise 2. Resistance Exercise i.e. 60 minutes per week of progressive resistance training |
| Exercise+Nutrition | Experimental | Dietary Supplement: Protein Supplementation, Other: Aerobic Exercise, Other: Resistance Exercise1. Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise 2. Dietary Supplement i.e. Protein Supplementation 1.2-1.5g/kg/body weight per day |
| Nutrition | Experimental | Dietary Supplement: Protein SupplementationDietary Supplement: Protein Supplementation i.e. 1.2-1.5g/kg/body weight per day |
Who may qualify
- Ages
- 60 to 90 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Male and Female participants
- 60 - 90 years of age
- Resident in North West, England, UK
- BMI 18.5-30 kg/m
- Can speak and understand English
Key exclusion criteria (11 listed)
- Recent (i.e. past 3 months) or concurrent participation in any clinical trial or dietary and/or exercise intervention program
- Self-reported lactose intolerance
- Uncontrolled diabetes (HbA1C >10)
- Uncontrolled Hypertension (160/100) and uncontrolled hypotension (<100 systolic)
- Treatment with Beta Blockers, Calcium Channel Blockers, Digitalis, Bronchodilator,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Protein Supplementation1.2-1.5g/kg/body weight per day | Dietary supplement | Exercise+Nutrition, Nutrition |
| Aerobic Exercise30-60 minutes per week of moderate intensity exercise | Other | Exercise, Exercise+Nutrition |
| Resistance Exercise60 minutes per week of progressive resistance training | Other | Exercise, Exercise+Nutrition |
Primary outcome
Body Composition: Lean Muscle/Fat Tissue 1) appendicular lean mass (kg) divided by height (meters-squared) and 2) appendicular lean mass divided by body mass index
Time frame: 16 weeks
19 secondary outcomes
Grip Strength: Hand Grip Dynanometer (kg)
Time frame: 16 weeks
Gait speed during timed 4-meter walk (m/s)
Time frame: 16 Weeks
Time to complete five chair rises (m/s)
Time frame: 16 Weeks
Balance assessment: 1) feet side to side, 2) semi-tandem, 3) full tandem, and 4) single leg. Scored as Yes or No.
Time frame: 16 Weeks
Isometric Strength - Knee Flexion/Extension: Dynanometer (Nm/Kg)
Time frame: 16 Weeks
Muscle Fatigue: Upper & Lower limb: 25% of MVC during 60 seconds using Electromyography (EMG), measured in millivolts (mV)
Time frame: 16 Weeks
Exercise Tolerance: Six Minute Walk Test (metres)
Time frame: 16 Weeks
10-metre Gait analysis during habitual walking speed using Electromyography (EMG)
Time frame: 16 Weeks
10-metre Gait analysis during habitual walking speed using Three-Dimensional Motion Capture - 1) Spatiotemporal, 2) Kinematics
Time frame: 16 Weeks
Biochemical: Glycated Haemoglobin (HBA1c) (%)
Time frame: 16 Weeks
Biochemical: C-Reactive Protein (CRP) (mg/L)
Time frame: 16 Weeks
Biochemical: Insulin-Like Growth Factor 1 (IGF-1) (ng/ml)
Time frame: 16 Weeks
Arterial Pressure: Pulse Wave Velocity (m/s)
Time frame: 16 Weeks
Energy Balance: Periodic Food Diary (Kcal)
Time frame: 16 Weeks
World Health Organization Quality Of Life Assessment (WHOQOL): Each question is scored from 1-5 on a response scale
Time frame: 16 Weeks
Short-Form Health Survey (SF-12): Each question is scored between 1-6 on a response scale
Time frame: 16 Weeks
Activities of Daily Living (ADL): Each response is scored as either: 0 or 1
Time frame: 16 Weeks
Mini-Mental State Examination (MMSE): Each correct response is scored as 1 point
Time frame: 16 Weeks
Nutritional Status: Mini-Nutritional Assessment (MNA) - Classified as (Low, Moderate, High risk)
Time frame: 16 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2025.
- Background: PubMed 20392703Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13.
- Background: PubMed 27023595Witard OC, Wardle SL, Macnaughton LS, Hodgson AB, Tipton KD. Protein Considerations for Optimising Skeletal Muscle Mass in Healthy Young and Older Adults. Nutrients. 2016 Mar 23;8(4):181. doi: 10.3390/nu8040181.
- Background: PubMed 25539836Lourenco RA, Perez-Zepeda M, Gutierrez-Robledo L, Garcia-Garcia FJ, Rodriguez Manas L. Performance of the European Working Group on Sarcopenia in Older People algorithm in screening older adults for muscle mass assessment. Age Ageing. 2015 Mar;44(2):334-8. doi: 10.1093/ageing/afu192. Epub 2014 Dec 23.
- Background: PubMed 26966433Yu SC, Khow KS, Jadczak AD, Visvanathan R. Clinical Screening Tools for Sarcopenia and Its Management. Curr Gerontol Geriatr Res. 2016;2016:5978523. doi: 10.1155/2016/5978523. Epub 2016 Feb 4.
- Background: PubMed 26894275Churchward-Venne TA, Holwerda AM, Phillips SM, van Loon LJ. What is the Optimal Amount of Protein to Support Post-Exercise Skeletal Muscle Reconditioning in the Older Adult? Sports Med. 2016 Sep;46(9):1205-12. doi: 10.1007/s40279-016-0504-2.
- Background: PubMed 26921660Kraschnewski JL, Sciamanna CN, Poger JM, Rovniak LS, Lehman EB, Cooper AB, Ballentine NH, Ciccolo JT. Is strength training associated with mortality benefits? A 15year cohort study of US older adults. Prev Med. 2016 Jun;87:121-127. doi: 10.1016/j.ypmed.2016.02.038. Epub 2016 Feb 24.
- Background: PubMed 26878863Witard OC, McGlory C, Hamilton DL, Phillips SM. Growing older with health and vitality: a nexus of physical activity, exercise and nutrition. Biogerontology. 2016 Jun;17(3):529-46. doi: 10.1007/s10522-016-9637-9. Epub 2016 Feb 15.
- Background: PubMed 26844538Chang SF, Lin PL. Systematic Literature Review and Meta-Analysis of the Association of Sarcopenia With Mortality. Worldviews Evid Based Nurs. 2016 Apr;13(2):153-62. doi: 10.1111/wvn.12147. Epub 2016 Feb 4.
- Background: PubMed 26302881Csapo R, Alegre LM. Effects of resistance training with moderate vs heavy loads on muscle mass and strength in the elderly: A meta-analysis. Scand J Med Sci Sports. 2016 Sep;26(9):995-1006. doi: 10.1111/sms.12536. Epub 2015 Aug 24.
- Background: PubMed 25268791Xu ZR, Tan ZJ, Zhang Q, Gui QF, Yang YM. Clinical effectiveness of protein and amino acid supplementation on building muscle mass in elderly people: a meta-analysis. PLoS One. 2014 Sep 30;9(9):e109141. doi: 10.1371/journal.pone.0109141. eCollection 2014.
- Background: PubMed 25809808Komar B, Schwingshackl L, Hoffmann G. Effects of leucine-rich protein supplements on anthropometric parameter and muscle strength in the elderly: a systematic review and meta-analysis. J Nutr Health Aging. 2015 Apr;19(4):437-46. doi: 10.1007/s12603-014-0559-4.
- Background: PubMed 20833863Ko SU, Hausdorff JM, Ferrucci L. Age-associated differences in the gait pattern changes of older adults during fast-speed and fatigue conditions: results from the Baltimore longitudinal study of ageing. Age Ageing. 2010 Nov;39(6):688-94. doi: 10.1093/ageing/afq113. Epub 2010 Sep 10.
- Individual participant dataSharing planned: Undecided
Related trials for Sarcopenia
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
MF-300 for Treatment of Age-Related Sarcopenia
Sarcopenia in Elderly
Not yet recruitingObservational study
Validation of Uzbek SARC-F and IPAQ-SF Questionnaires in Adults With and Without Hypothyroidism
Hypothyroidism, Psychometrics
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dr Omid Alizadehkhaiyat, MD, PhD principal investigator
Liverpool Hope University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Protein Supplementation, Aerobic Exercise and Resistance Exercise in people with Sarcopenia and Muscular Atrophy, run by Liverpool Hope University at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Body Composition: Lean Muscle/Fat Tissue 1) appendicular lean mass (kg) divided by height (meters-squared) and 2) appendicular lean mass divided by body mass index (time frame: 16 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02912130, which also lists 14 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2025.